Valuation Matinas BioPharma Holdings, Inc.
Stocks
MTNB
US5768104029
Biotechnology & Medical Research
|
Delayed
NYSE
12:56:27 2026-10-01 EDT
|
5-day change | 1st Jan Change | ||
| 2.510 USD | -1.57% |
|
-5.99% | -71.44% |
| 08-20 | Top Premarket Decliners | MT |
| 08-13 | Matinas BioPharma Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
Company Valuation: Matinas BioPharma Holdings, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Market Cap 1 | 271.5 | 218.4 | 108.4 | 46.97 | 2.594 | 3.754 |
| Change | - | -19.56% | -50.35% | -56.68% | -94.48% | 44.7% |
| Enterprise Value (EV) 1 | 216.6 | 173.5 | 83.79 | 36.77 | -1.796 | 1.109 |
| Change | - | -19.9% | -51.7% | -56.11% | -104.88% | 161.76% |
| P/E | -11.5x | -8.96x | -5.16x | -2.05x | -0.1x | -0.29x |
| PBR | 4.54x | 4.16x | 2.97x | 2.44x | 0.34x | 0.78x |
| PEG | - | 1.97x | 0.4x | -0.23x | 0.02x | 0x |
| Capitalization / Revenue | 1,715x | 6,552x | 34x | 42.9x | - | - |
| EV / Revenue | 1,368x | 5,205x | 26.3x | 33.6x | - | - |
| EV / EBITDA | -9.06x | -7.09x | -3.46x | -1.57x | 0.09x | -0.16x |
| EV / EBIT | -8.95x | -7.01x | -3.41x | -1.55x | 0.09x | -0.16x |
| EV / FCF | -22.2x | -21x | -5.82x | -5.37x | 0.24x | -0.33x |
| FCF Yield | -4.51% | -4.75% | -17.2% | -18.6% | 415% | -301% |
| Dividend per Share 2 | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - |
| EPS 2 | -88.53 | -84.5 | -72.63 | -79.2 | -74.76 | -30.04 |
| Distribution rate | - | - | - | - | - | - |
| Net sales 1 | 0.1583 | 0.0333 | 3.188 | 1.096 | - | - |
| EBITDA 1 | -23.92 | -24.45 | -24.23 | -23.37 | -19.79 | -6.924 |
| EBIT 1 | -24.21 | -24.73 | -24.59 | -23.77 | -20.16 | -6.96 |
| Net income 1 | -22.45 | -23.28 | -21 | -22.94 | -24.25 | -10.34 |
| Net Debt 1 | -54.93 | -44.92 | -24.64 | -10.2 | -4.39 | -2.645 |
| Reference price 2 | 1,020.000 | 757.500 | 375.000 | 162.150 | 7.650 | 8.790 |
| Nbr of stocks (in thousands) | 266 | 288 | 289 | 290 | 339 | 427 |
| Announcement Date | 3/29/21 | 3/8/22 | 3/15/23 | 3/27/24 | 4/15/25 | 3/31/26 |
1USD in Million2USD
Estimates
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | - | - | - | 2.5M | |
| 21.73x | 7.77x | 15.61x | 1.37% | 74.46B | |
| 31.25x | 9.01x | 28.06x | 0.04% | 60.14B | |
| 33.64x | 6.03x | 18.07x | 0.97% | 48.15B | |
| 34.63x | 3.34x | 14.4x | -.--% | 44.25B | |
| -21.16x | 229.18x | -22.81x | -.--% | 43.99B | |
| 47.94x | 5.54x | 30.43x | -.--% | 41.61B | |
| 26.89x | 7.76x | 19.96x | 0.42% | 29.97B | |
| 33.91x | 7.26x | 18.84x | -.--% | 29.31B | |
| -70.02x | 13.44x | -68.51x | -.--% | 24.93B | |
| Average | 15.42x | 32.15x | 6.01x | 0.31% | 39.68B | |
| Weighted average by Cap. | 19.58x | 31.88x | 10.24x | 0.41% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- MTNB Stock
- Valuation Matinas BioPharma Holdings, Inc.
Select your edition
All financial news and data tailored to specific country editions
